Why Valeant Pharmaceuticals Intl Inc. Will Fail to Re-Invent Itself

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had a horrible year, and I believe the stock is far from rallying.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had an abysmal year as the stock plummeted 86%. The company wants to re-invent itself to become a dominant player in the pharmaceutical scene again.

There were huge changes made this year as ex-CEO Michael Pearson stepped out and Joseph Papa stepped in. Joseph Papa is an excellent choice as the new CEO, and he’s got a ton of incentive to bring the company out of the gutter, but I believe he’s in way over his head. Valeant has severely damaged its reputation with investors across the globe, and I don’t believe anything can reverse what has already happened.

As Warren Buffett once said, “It takes 20 years to build a reputation and five minutes to ruin it.”. To say Valeant’s reputation has been ruined is an understatement.

The company has faced so many scandals and endured so many short attacks that even the most contrarian of investors are avoiding this stock like the plague. Charlie Munger, Warren Buffett’s right-hand man, even went as far as to call the company a “sewer.” These are strong words put forth by the guru, but I believe he’s right on the spot with his statement.

There are many contrarian investors that are looking to gain a quick profit by trying to get into Valeant. But there doesn’t appear to be a bottom, and the upside may be limited considering the company’s ruined reputation.

Activist investor Bill Ackman is now on the board of directors, and he’s still fully invested, even after the massive decline the stock faced over the past year and a half. Don’t follow Ackman into this one. Most of his original investment is already gone, and he’s just trying to recover some of his losses, but I don’t believe he’ll be successful.

Valeant still has $8 billion worth of debt and will need to sell its non-core assets at a loss. Buying high and selling low is never a good strategy to make money, and I believe the company will remain on damage control for the next few years before the stock can start moving higher.

Even if you’re a believer in Bill Ackman and the new CEO Joseph Papa, any upside in 2017 will be very modest, and there’s still the risk of a further correction as more disappointing earnings reports come in. There is also the risk of having more scandals should there be any shady findings from investigations going forward.

If you’re a contrarian investor, then steer clear of Valeant. Its reputation is permanently damaged, and it’s not going to soar anytime soon. There’s still a huge mess that Michael Pearson left, and it won’t be cleaned up anytime soon.

I have one simple rule. If there’s any sign of shady activity in a company’s history, then that makes the stock an automatic sell. Don’t even think about picking up share in Valeant unless you’re willing to lose it all.

Fool contributor Joey Frenette has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

man looks surprised at investment growth
Dividend Stocks

This 6% Dividend Stock Pays Cash Every Single Month

Given its strong financial position and solid growth prospects, Whitecap appears well-equipped to reward shareholders with higher dividend yields, making…

Read more »

Dividend Stocks

1 Canadian Dividend Stock Down 33% Every Investor Should Own

A freight downturn has knocked TFI International’s stock, but its discipline and safe dividend could turn today’s dip into tomorrow’s…

Read more »

Person holds banknotes of Canadian dollars
Dividend Stocks

The 7.3% Dividend Gem Every Passive-Income Investor Should Know About

Buying 1,000 shares of this TSX stock today would generate about $154 per month in passive income based on its…

Read more »

businesswoman meets with client to get loan
Dividend Stocks

A Top-Performing U.S. Stock for Canadian Investors to Buy and Hold

Berkshire Hathaway (NYSE:BRK.B) is a top U.s. stock for canadians to hold.

Read more »

Map of Canada showing connectivity
Dividend Stocks

Buy Canadian: 1 TSX Stock Set to Outperform Global Markets in 2026

Nutrien’s potash scale, global retail network, and steady fertilizer demand could make it the TSX’s quiet outperformer in 2026.

Read more »

A worker overlooks an oil refinery plant.
Energy Stocks

A Canadian Energy Stock Poised for Big Growth in 2026

Enbridge (TSX:ENB) is an oft-forgotten energy stock, but one with an excellent yield and newfound growth potential worth considering in…

Read more »

dumpsters sit outside for waste collection and trash removal
Energy Stocks

Could This Undervalued Canadian Stock Be Your Ticket to Millionaire Status

Valued at a market cap of $600 million, Aduro is a small-cap Canadian stock that offers massive upside potential in…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

TFSA Investors: How Couples Can Earn $10,700 Per Year in Tax-Free Passive Income

Here's one interesting way that couples could earn as much as $10,700 of tax-free income inside their TFSA in 2026.

Read more »